Site Map
- Home
- Pipeline
- Our Team
- Management
- Patrick J. McEnany
- Charles W. Gorodetzky, MD, PhD
- Alicia Grande, CPA, CMA
- Steven R. Miller, PhD
- Richard P. Rieger
- M. Douglas Winship
- Board of Directors
- Patrick J. McEnany
- Philip H. Coelho
- Hubert E. Huckel, MD
- Charles B. O'Keeffe
- David S. Tierney, MD
- Milton J. Wallace
- Scientific Advisory Board
- Stephen L. Dewey, PhD
- Jonathan Brodie, PhD, MD
- Robert D. Fechtner, MD
- Thomas Kosten, MD
- Eugene Laska, PhD
- Richard A. Rawson, PhD
- Richard B. Silverman, PhD
- News
- 11/09 — The American Journal of Psychiatry, article (PDF) and editorial (PDF) Positive results for Catalyst's 2007 Phase II trial in Mexico
- 11/13/08 — SynapseSynapse reports that vigabatrin blocks reinstatement of drug-seeking behavior in animals.
- 8/20/08 — SynapseGenetically bred “fat rats” given vigabatrin experience dramatic weight loss.
- 3/3/08 — Newsweek (PDF version) Cover story: "What Addicts Need"
- 12/18/07 — Rodman & Renshaw, transcript (PDF)
Rodman & Renshaw rates Catalyst "Market Outperform." - 12/07 — The Ones to Watch (PDF)
Thomson Scientific rates CPP-109. See page 7 - 7/16/07 — BioCentury"Product Development: Down-sizing the High"
- 7/05/07 — TIME magazine"How We Get Addicted"
- 2/16/07 — Long Island Newsday"Dulling dopamine's kick"
- 1/14/07 — Miami Herald"Catalyst focuses on drug to treat addicts"
- 4/21/05 — Senate TestimonyNora D. Volkow, MD, Director of NIDA, discusses promise of CPP-109
- 12/10/04 — VentureWire Lifescience"Catalyst Looks for $10M Series B as it Plans Clinical Trials"
- 2/15/04 — NIDA Notes"The Long Road to Medication Development: Cocaine Treatment Moves to Clinical Trials"
- Investors
- Links
- Contact Us
- SITE MAP
What’s New
Catalyst has acquired exclusive worldwide rights to commercialize novel GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by Northwestern University. More ยป